Imprimis Pharmaceuticals announced it has formally changed its name to Harrow Health and began trading as “HROW” on the NASDAQ Capital Markets on January 2, 2019.
“Our new name reflects our business model of creating, investing in, operating and growing a diversified portfolio of healthcare businesses that meet the needs of healthcare providers and patients across America,” Mark L. Baum, CEO of Harrow Health, said in a company news release. “The future of healthcare involves rethinking our current paradigm, creating patient-centric solutions, and motivating the best partners to act to turn vision into reality. I’ve never been more enthusiastic about our ability to execute our strategy and the value Harrow Health will deliver over many years to come.”
Harrow Health’s businesses and subsidiaries each have strong brand equity and will continue to operate under the Harrow Health corporate umbrella using their existing names. This includes Harrow Health’s wholly-owned subsidiaries ImprimisRx, an ophthalmology pharmaceutical compounding business, and Park Compounding. Harrow Health’s equity interests and royalty-rights in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals, and Radley Pharmaceuticals remain in Harrow Health as well.